PMID- 32509092
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200611
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 13
IP  - 5
DP  - 2020
TI  - Aberrant expression of WWOX and its association with cancer stem cell biomarker 
      expression.
PG  - 1176-1184
AB  - BACKGROUND: Nanog and CD133 are biomarkers of cancer stem cells (CSCs) that 
      regulate cancer progression. The WW domain-containing oxidoreductase (WWOX) is a 
      tumor suppressor protein that can inhibit tumor cell proliferation. The purpose 
      of this study was to investigate the expression and clinical significance of 
      Nanog, CD133, and WWOX in infiltrating breast cancer (IBC). METHODS: Expressions 
      of Nanog, CD133, and WWOX in 204 IBC specimens and their corresponding control 
      specimens were detected by immunohistochemistry. Patients' clinicopathologic and 
      follow-up data were also collected. RESULTS: The rates of positive expression of 
      Nanog and CD133 were significantly higher in IBC specimens than in control 
      specimens, and their expression was positively associated with tumor size, grade, 
      and tumor stages, lymph node metastasis (LNM), and tumor-node-metastasis (TNM) 
      stage. The rate of positive expression of WWOX was significantly lower in IBC 
      specimens than in control specimens, and its expression was inversely associated 
      with tumor size, grade, and tumor stages, LNM, and TNM stage. Patients whose 
      specimens expressed Nanog, CD133, or HER2 had a reduced overall survival (OS) 
      when compared with patients not expressing these proteins. However, patients 
      whose specimens expressed WWOX, ER, or PR had an increased OS when compared with 
      patients who did not show expression. Multivariate analysis demonstrated that 
      expression of Nanog, CD133, WWOX, ER, and HER2, and the TNM stage were 
      independent prognostic factors for IBC patients. CONCLUSIONS: Therefore, Nanog, 
      CD133, and WWOX should be considered as promising prognostic factors and 
      therapeutic targets in IBC.
CI  - IJCEP Copyright (c) 2020.
FAU - Zhai, Yunzhi
AU  - Zhai Y
AD  - Department of Medical Oncology, Pathology, The First Affiliated Hospital of 
      Bengbu Medical College Anhui, China.
FAU - Han, Yajuan
AU  - Han Y
AD  - Department of Medical Oncology, Pathology, The First Affiliated Hospital of 
      Bengbu Medical College Anhui, China.
FAU - Han, Zhengquan
AU  - Han Z
AD  - Department of Medical Oncology, Pathology, The First Affiliated Hospital of 
      Bengbu Medical College Anhui, China.
LA  - eng
PT  - Journal Article
DEP - 20200501
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
PMC - PMC7270669
OTO - NOTNLM
OT  - CD133
OT  - Infiltrating breast cancer
OT  - Nanog
OT  - WWOX
OT  - cancer stem cells
OT  - prognosis
COIS- None.
EDAT- 2020/06/09 06:00
MHDA- 2020/06/09 06:01
PMCR- 2020/05/01
CRDT- 2020/06/09 06:00
PHST- 2020/03/14 00:00 [received]
PHST- 2020/04/16 00:00 [accepted]
PHST- 2020/06/09 06:00 [entrez]
PHST- 2020/06/09 06:00 [pubmed]
PHST- 2020/06/09 06:01 [medline]
PHST- 2020/05/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2020 May 1;13(5):1176-1184. eCollection 2020.